1.Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64.
2.Thrift AP, El-Serag HB. Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–42.
3.Meng LB, Shan MJ, Qiu Y, Qi R, Yu ZM, Guo P, et al. TPM2 as a potential predictive biomarker for atherosclerosis. Aging (Albany NY). 2019;11(17):6960–82.
4.Sun CC, Zhou Q, Hu W, Li SJ, Zhang F, Chen ZL, et al. Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 2018;10(5):973–87.
5.Huang C, Liu Z, Xiao L, Xia Y, Huang J, Luo H, et al. Clinical Significance of Serum CA125, CA19–9, CA72–4, and Fibrinogen-to-Lymphocyte Ratio in Gastric Cancer With Peritoneal Dissemination. Front Oncol. 2019;9:1159.
6.Szabo L, Salzman J. Detecting circular RNAs: bioinformatic and experimental challenges. Nat Rev Genet. 2016;17(11):679–92.
7.Scarpazza C, Tognin S, Frisciata S, Sartori G, Mechelli A. False positive rates in Voxel-based Morphometry studies of the human brain: should we be worried. Neurosci Biobehav Rev. 2015;52:49–55.
8.Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41(Database issue):D991–5.
9.Li L, Zhu Z, Zhao Y, Zhang Q, Wu X, Miao B, et al. FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics. Sci Rep. 2019;9(1):7827.
10.Ren F, Zhao Q, Liu B, Sun X, Tang Y, Huang H, et al. Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer. J Cell Physiol. 2020;235(3):2738–52.
11.Chivu EM, Necula LG, Dragu D, Badea L, Dima SO, Tudor S, et al. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology. 2010;57(104):1453–64.
12.Nanki K, Toshimitsu K, Takano A, Fujii M, Shimokawa M, Ohta Y, et al. Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis. Cell. 2018;174(4):856–69.e17.
13.Hess AS, Hess JR, AUID- Oho. Principal component analysis. Transfusion. 2018;58(7):1580–2.
14.Song ZY, Chao F, Zhuo Z, Ma Z, Li W, Chen G. Identification of hub genes in prostate cancer using robust rank aggregation and weighted gene co-expression network analysis. Aging (Albany NY). 2019;11(13):4736–56.
15.Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3.
16.Zhou Y, Zhou B, Pache L, Chang M, 0000–0002–4526–489X AO, Khodabakhshi AH, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
17.Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res. 2017;45(W1):W130–130W137.
18.Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–362D368.
19.Otasek D, Morris JH, Boucas J, Pico AR, Demchak B, 0000–0001–7065–7786 AO. Cytoscape Automation: empowering workflow-based network analysis. Genome Biol. 2019;20(1):185.
20.Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, et al. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14:83.
21.Rugge M, Genta RM, Di MF, El-Omar EM, El-Serag HB, Fassan M, et al. Gastric Cancer as Preventable Disease. Clin Gastroenterol Hepatol. 2017;15(12):1833–43.
22.McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11(11):664–74.
23.Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79(2):127–32.
24.Mashima T, Iwasaki R, Kawata N, Kawakami R, Kumagai K, Migita T, et al. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. Br J Cancer. 2019;121(10):846–56.
25.Honjo K, Munakata S, Tashiro Y, Salama Y, Shimazu H, Eiamboonsert S, et al. Plasminogen activator inhibitor–1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice. FASEB J. 2017;31(6):2625–37.
26.Pirzer T, 0000–0001–9671–6289 AO, Becher KS, Rieker M, Meckel T, 0000–0003–0759–2072 AO, et al. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins. ACS Chem Biol. 2018;13(8):2058–66.
27.Chen S, Qiu Y, Guo P, Pu T, Feng Y, Bu H. FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis. Oncol Lett. 2018;15(6):8206–14.
28.Nardone B, Nicholson K, Newman M, Guitart J, Gerami P, Talarico N, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res. 2010;16(17):4452–60.
29.Xu DH, Li Q, Hu H, Ni B, Liu X, Huang C, et al. Transmembrane protein GRINA modulates aerobic glycolysis and promotes tumor progression in gastric cancer. J Exp Clin Cancer Res. 2018;37(1):308.
30.Zhang B, Wu J, Cai Y, Luo M, Wang B, Gu Y. AAED1 modulates proliferation and glycolysis in gastric cancer. Oncol Rep. 2018;40(2):1156–64.
31.Saadi A, Shannon NB, Lao-Sirieix P, O’Donovan M, Walker E, Clemons NJ, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A. 2010;107(5):2177–82.
32.Hayakawa Y, Sakitani K, Konishi M, Asfaha S, Niikura R, Tomita H, et al. Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling. Cancer Cell. 2017;31(1):21–34.
33.Jin H, Wang Z, Liu L, Gao L, Sun L, Li X, et al. R-flurbiprofen reverses multidrug resistance, proliferation and metastasis in gastric cancer cells by p75(NTR) induction. Mol Pharm. 2010;7(1):156–68.
34.Du F, Feng W, Chen S, Wu S, Cao T, Yuan T, et al. Sex determining region Y-box 12 (SOX12) promotes gastric cancer metastasis by upregulating MMP7 and IGF1. Cancer Lett. 2019;452:103–18.
35.Xu L, Hou Y, Tu G, Chen Y, Du YE, Zhang H, et al. Nuclear Drosha enhances cell invasion via an EGFR-ERK1/2-MMP7 signaling pathway induced by dysregulated miRNA–622/197 and their targets LAMC2 and CD82 in gastric cancer. Cell Death Dis. 2017;8(3):e2642.
36.Bornschein J, Seidel T, Langner C, Link A, Wex T, Selgrad M, et al. MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression. Diagn Pathol. 2015;10:212.
37.Hibi K, Kitamura YH, Mizukami H, Goto T, Sakuraba K, Sakata M, et al. Frequent CDH3 demethylation in advanced gastric carcinoma. Anticancer Res. 2009;29(10):3945–7.
38.Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet. 2009;18(9):1545–55.
39.Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008;14(20):6487–95.
40.Wang J, Liu H, Zheng K, Zhang S, Dong W. MicroRNA–6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1. Exp Ther Med. 2019;18(3):1877–83.
41.Tang X, Zheng D, Hu P, Zeng Z, Li M, Tucker L, et al. Glycogen synthase kinase 3 beta inhibits microRNA–183–96–182 cluster via the beta-Catenin/TCF/LEF–1 pathway in gastric cancer cells. Nucleic Acids Res. 2014;42(5):2988–98.
42.Jeong EG, Lee SH, Yoo NJ, Lee SH. Mutational analysis of Wnt pathway gene LEF1 in common human carcinomas. Dig Liver Dis. 2007;39(3):287–8.